European Patent Office

T 0670/20 (Pharmaceutcial composition/SANKYO) du 02.12.2022

Identifiant européen de la jurisprudence
ECLI:EP:BA:2022:T067020.20221202
Date de la décision
2 décembre 2022
Numéro de l'affaire
T 0670/20
Requête en révision de
-
Numéro de la demande
08720658.7
Langue de la procédure
Anglais
Distribution
Distribuées aux présidents des chambres de recours (C)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Résumés pour cette décision
Résumé de EPC2000 Art 054
Titre de la demande
PHARMACEUTICAL COMPOSITION
Nom du demandeur
Daiichi Sankyo Company, Limited
Nom de l'opposant
Hexal AG
Generics [UK] Ltd
Chambre
3.3.07
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 013(1)
Mots-clés
Amendments - allowable (yes)
Novelty - public prior use (no)
Inventive step - bonus effect (no)
Amendment to appeal case - justification by party (yes)
Exergue
The clinical trials were carried out in accordance with the EMEA Guidelines for Good Clinical Practice. These guidelines explicitly require adherence to the prescribed protocol and assurance of drug accountability. This set-up of the trials implies that the patients who decided to participate in the trials agreed, following their informed consent, to use the provided medication according to instruction or to return the unused medication. Accordingly, the participating patients who were provided with the tablets under investigation entered into a special relationship with the investigators of the trials and were with regard to the provided tablets not members of the public that could freely dispose over these tablets. (see section 4.3)
Affaires citées
T 0192/82T 0007/07
Affaires citantes
-

Order

For these reasons it is decided that:

The appeals are dismissed.